Table 2

Univariate analysis of prognostic factors
Univariate analysis n % 3-y-LC p-value 3-y-DC p-value 3-y-OS p-value
all patients 97 100 52% 48% 52%
age
< 60 yrs 47 48 49% 0.329 50% 0.522 48% 0.619
≥ 60 yrs 50 52 55% 47% 55%
gender
male 59 61 44% 0.023 52% 0.779 53% 0.701
female 38 39 65% 42% 54%
time FD to rec
< 30 mo 48 49 49% 0.308 46% 0.389 43% 0.398
≥ 30 mo 49 51 55% 50% 61%
T stage (FD)*
T1/2 34 35 64% 0.13 61% 0.056 70% 0.045
T3/4 62 64 43% 40% 43%
N stage (FD)*
N0 54 56 61% 0.008 53% 0.047 60% 0.06
N+ 41 42 39% 42% 37%
UICC stage (FD)*
I/II 53 55 60% 0.015 55% 0.03 62% 0.046
III/IV 42 43 41% 41% 41%
resection margin
R0 36 37 82% < 0.001 55% 0.047 80% < 0.001
R1 32 33 41% 42% 37%
R2 29 30 18% 48% 35%
EBRT
yes 54 56 59% 0.062 49% 0.928 60% 0.18
no 43 44 41% 50% 43%
EBRT
neoadj RT 46 47 61% 0.067 51% 0.797 59% 0.284
no RT 43 44 41% 50% 43%
adj. CHT
yes 33 34 50% 0.817 54% 0.945 63% 0.745
no 64 66 54% 47% 45%
resection of met
yes 20 21 65% 0.358 35% 0.155 47% 0.484
no 77 79 49% 52% 54%
local control achieved
yes 52 54 not amendable 53% 0.2 55% 0.03
no 45 46 43% 52%

n: number of patients, %: percentage, 3-y-LC: three-year local control, 3-y-DC: three-year distant control, 3-y-OS: three-year overall survival, yrs: years, FD: first diagnosis, rec: local recurrence, mo: months, *: based on 95 patients with known stage at first diagnosis, UICC: Union internationale contre le cancer, R0: complete resection without microscopic residual disease, R1: microscopic residual disease, R2: gross residual disease, EBRT: external beam radiation therapy, RT: radiotherapy, adj.: adjuvant, CHT: chemotherapy, met.: distant metastasis.

Roeder et al.

Roeder et al. BMC Cancer 2012 12:592   doi:10.1186/1471-2407-12-592

Open Data